Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Merkel Cell Carcinoma

Merkel Cell Carcinoma

Part of Germ cell tumors

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Merkel Cell Carcinoma

7 trials tracked for Merkel Cell Carcinoma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 6 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Other / NA 1
  1. Phase 3 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Completed · 6 cited
  2. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  3. Phase 2 Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) Completed
  4. Phase 2 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Completed
  5. Phase 2 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Completed
  6. Phase 2 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Completed
Show 1 more trials
  1. N/A The Impact of Total Body Skin Examination on Skin Cancer Detection Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PD-L1 expression shows subtype-specific prognostic value in skin neoplasms, meta-analysis finds
Dermatology Meta-analysis
PD-L1 expression shows subtype-specific prognostic value in skin neoplasms, meta-analysis finds Does a common cancer marker predict survival in skin cancers? It depends
A meta-analysis of 24 observational studies found PD-L1 expression was not significantly associated with overall survival (HR=0.89, 95% CI: …
A common skin cancer marker doesn't predict survival for everyone, but it does for specific types like Merkel cell carcinoma and melanoma.
Apr 6, 2026
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
Oncology FDA Approval
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma FDA approves new drug Zynyz for two rare and aggressive types of cancer
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.
FDA Apr 2, 2026